MedTrace Logo

Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds

NCT06730022 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-02-25

No results posted yet for this study

Summary

The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.

Conditions

  • Cutaneous Ulcer
  • Diabetic Ulcer
  • Surgical Wound Dehiscence
  • Burns - Multiple
  • Pressure Ulcers
  • Mixed Ulcer
  • Ischemic Ulcer

Interventions

DRUG

MTX-001 (Dermacyte Liquid)

Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.

Sponsors & Collaborators

  • Merakris Therapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06730022 on ClinicalTrials.gov